Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs

Human Gene Therapy

Volumn 23, Issue 3, 2012, Pages 287-294

  Shin, Jin Hong ^a   Yue, Yongping ^a   Smith, Bruce ^b   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; VIRUS ANTIBODY; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 6; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GENE VECTOR; HUMORAL IMMUNITY; IN VITRO GENE TRANSFER; IN VITRO STUDY; MALE; NEWBORN; NONHUMAN; SEROPREVALENCE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ANIMALS; ANTIBODIES, NEUTRALIZING; DEPENDOVIRUS; DOGS; DYSTROPHIN; GENETIC THERAPY; GENETIC VECTORS; IMMUNITY, HUMORAL; MUSCULAR DYSTROPHY, ANIMAL; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS 6; CANIS FAMILIARIS; PARVOVIRUS;

EID: 84863419418     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.125     Document Type: Article

References (49)

1. Atchison, R.W., Casto, B.C., and Hammon, W.M. (1965). Adenovirus-associated defective virus particles. Science 149, 754-756.
2. Bostick, B., Ghosh, A., Yue, Y., et al. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14, 1605-1609. (Pubitemid 350056232)
3. Bostick, B., Yue, Y., Lai, Y., et al. (2008). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum. Gene Ther. 19, 851-856.
4. Bouchard, G., Plata-Madrid, H., Youngquist, R.S., et al. (1992). Absorption of an alternate source of immunoglobulin in pups. Am. J. Vet. Res. 53, 230-233.
5. Calcedo, R., Vandenberghe, L.H., Gao, G., et al. (2009). Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J. Infect. Dis. 199, 381-390.
6. Cooper, B.J., Winand, N.J., Stedman, H., et al. (1988). The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334, 154-156.
7. Day, M.J. (2007). Immune system development in the dog and cat. J. Comp. Pathol. 137 Suppl 1, S10-S15. (Pubitemid 46978057)
8. Duan, D. (2011). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2, 31-42.
9. Felsburg, P.J. (1998). Immunology of the dog. In Handbook of Vertebrate Immunology. P.P. Pastoret, P. Griebel, H. Bazin, and A. Govaerts, eds. Academic Press New York, NY, pp 261-288.
10. Felsburg, P.J. (2002). Overview of immune system development in the dog: comparison with humans. Hum. Exp. Toxicol. 21, 487-492. (Pubitemid 35385985)
11. Fine, D.M., Shin, J.H., Yue, Y., et al. (2011). Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul. Disord. XX, XX-XX.
12. Gao, G., Vandenberghe, L.H., Alvira, M.R., et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388. (Pubitemid 38715936)
13. Gao, G., Vandenberghe, L.H., and Wilson, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297. (Pubitemid 40895013)
14. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. (Pubitemid 34994488)
15. Ghosh, A., Yue, Y., Long, C., et al. (2007). Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol. Ther. 15, 750-755. (Pubitemid 46431995)
16. Gregorevic, P., Allen, J.M., Minami, E., et al. (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787-789. (Pubitemid 44050067)
17. Gregorevic, P., Schultz, B.R., Allen, J.M., et al. (2009). Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol. Ther. 17, 1427-1433.
18. Halbert, C.L., Miller, A.D., McNamara, S., et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum. Gene Ther. 17, 440-447.
19. Harper, S.Q., Hauser, M.A., Dellorusso, C., et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261. (Pubitemid 34250103)
20. Heddle, R.J., and Rowley, D. (1975). Dog immunoglobulins. I. Immunochemical characterization of dog serum, parotid saliva, colostrum, milk and small bowel fluid. Immunology 29, 185-195.
21. Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., et al. (2010). Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983-1994.
22. Korhonen, H., Marnila, P., and Gill, H.S. (2000). Milk immunoglobulins and complement factors. Br. J. Nutr. 84 Suppl 1, S75-S80. (Pubitemid 32106832)
23. Kornegay, J.N., Tuler, S.M., Miller, D.M., and Levesque, D.C. (1988). Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11, 1056-1064.
24. Lai, Y., Thomas, G.D., Yue, Y., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635.
25. Mingozzi, F., and High, K.A. (2011). Immune responses to AAV in clinical trials. Curr. Gene Ther. 11, 321-330.
26. Ohshima, S., Shin, J.H., Yuasa, K., et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther. 17, 73-80.
27. Poffenbarger, E.M., Olson, P.N., Chandler, M.L., et al. (1991). Use of adult dog serum as a substitute for colostrum in the neonatal dog. Am. J. Vet. Res. 52, 1221-1224.
28. Pollock, R.V., and Carmichael, L.E. (1982). Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J. Am. Vet. Med. Assoc. 180, 37-42. (Pubitemid 12155741)
29. Qiao, C., Zhang, W., Yuan, Z., et al. (2010). AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther. 21, 1343-1348.
30. Rapti, K., Louis-Jeune, V., Kohlbrenner, E., et al. (2011). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther. In-press. doi:10.1038/mt.2011.177.
31. Reynolds, H.Y., and Johnson, J.S. (1970). Quantitation of canine immunoglobulins. J. Immunol. 105, 698-703.
32. Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309-319. (Pubitemid 28048842)
33. Schafer-Somi, S., Bar-Schadler, S., and Aurich, J.E. (2005). Immunoglobulins in nasal secretions of dog puppies from birth to six weeks of age. Res. Vet. Sci. 78, 143-150. (Pubitemid 39618907)
34. Sharp, N.J., Kornegay, J.N., Van Camp, S.D., et al. (1992). An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13, 115-121.
35. Shelton, G.D., and Engvall, E. (2005). Canine and feline models of human inherited muscle diseases. Neuromuscul. Disord. 15, 127-138. (Pubitemid 40202739)
36. Shin, J.H., Yue, Y., Srivastava, A., et al. (2011). A simplified immune suppression scheme leads to persistent microdystrophin expression in Duchenne muscular dystrophy dogs. Hum. Gene Ther. In-press. doi:10.1089/hum.2011.147.
37. Smith, B.F., Kornegay, J.N., and Duan, D. (2007). Independent canine models of Duchenne muscular dystrophy due to intronic insertions of repetitive DNA. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA. May 30-June 3, 2007.
38. Smith, B.F., Yue, Y., Woods, P.R., et al. (2011). An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab. Invest. 91, 216-231.
39. Vandenberghe, L.H., and Wilson, J.M. (2007). AAV as an immunogen. Curr. Gene Ther. 7, 325-333. (Pubitemid 47595775)
40. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 97, 13714-13719.
41. Wang, L., Calcedo, R., Wang, H., et al. (2010). The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol. Ther. 18, 126-134.
42. Wang, Z., Kuhr, C.S., Allen, J.M., et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160-1166. (Pubitemid 46813619)
43. Xiao, W., Chirmule, N., Berta, S.C., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003. (Pubitemid 29189844)
44. Yue, Y., Li, Z., Harper, S.Q., et al. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626-1632. (Pubitemid 37187791)
45. Yue, Y., Liu, M., and Duan, D. (2006). C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin- associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol. Ther. 14, 79-87. (Pubitemid 43922138)
46. Yue, Y., Ghosh, A., Long, C., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
47. Yue, Y., Shin, J.-H., and Duan, D. (2011). Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol. Biol. 709, 313-329.
48. Zaiss, A.K., and Muruve, D.A. (2008). Immunity to adenoassociated virus vectors in animals and humans: a continued challenge. Gene Ther. 15, 808-816. (Pubitemid 351712613)
49. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105, 7827-7832. (Pubitemid 351872723)